HYRIMOZ is the
biosimilar to
Humira® worldwidea
Available in
countries
Prescribed to
globally
aBased on an analysis of volume of worldwide sales (in KG) for the period March to August 2022. Not all products were available in all countries surveyed. Analysis included Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine, Algeria, Argentina, Australia, Brazil, Central America, Canada, Chile, China, Colombia, Egypt, Fr. W. Africa, Japan, Jordan, Kazakhstan, Korea, Kuwait, Lebanon, Mexico, Morocco, New Zealand, Peru, Saudi Arabia, South Africa, Taiwan, Turkey, UAE, and US.
What can you expect with HYRIMOZ?
AN FDA-APPROVED TREATMENT
HYRIMOZ is approved to treat Psoriatic Arthritis, Ankylosing Spondylitis, and Moderate-to-Severe: Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis (≥2 years of age), Crohn’s Disease (Adult and Pediatric, ≥6 years of age), Ulcerative Colitis, Chronic Plaque Psoriasis, and Hidradenitis Suppurativa. See full uses for HYRIMOZ below.
SIMILAR symptom relief
Studies show there are no clinically meaningful differences between HYRIMOZ and Humira® when it comes to safety, effectiveness, or quality.
The same dosing
HYRIMOZ has the same dosing options as Humira®, so switching is straightforward. HYRIMOZ is available in the Sensoready® pen autoinjector or a prefilled syringe.
SUPPORT at every step
People taking HYRIMOZ have access to many support services through Sandoz One Source, including Nurse Ambassadors, 1:1 injection training, financial support, and more.
Real people, real results
HYRIMOZ has been available outside the United States since 2018 and has been prescribed to more than 300,000 people worldwide!
What does it mean to be a biosimilar to Humira®?
A biosimilar like HYRIMOZ is a medicine that is highly similar to a name-brand medication like Humira®. "Highly similar" means there are no clinically meaningful differences between the 2 medicines when it comes to safety, effectiveness, or quality.
HYRIMOZ delivers results.
See how HYRIMOZ works for people with different conditions.b Individual results may vary.
See full uses for HYRIMOZ below.
HYRIMOZ may help if you have:
- Reduce your number of tender and swollen joints
- Prevent further progression of joint damagec
- cAs seen in 50% of patients treated with adalimumab and methotrexate after 5 years.
- Reduce your joint pain
- Stop further joint damage (after 24 weeks) and reduce joint damage (at 48 weeks)
- Achieve remission
- Approximately 40% of adults and 28% of pediatric patients achieved remission at 26 weeks
- Achieve clearer skin
- Approximately 62% of patients achieved minimal or clear skin at 16 weeks
- Reduce your number of flare-ups
- Reduce the use of corticosteroids for people also using methotrexate
- Reduce your back pain
- Improve your spinal mobility and flexibility
- Achieve remission
- Approximately 18.5% of adults achieved remission at 8 weeks
- Reduce your number of lesions (abscesses or inflammatory nodules)
- Prevent additional abscesses and draining lesions
bBased on clinical studies with Humira® and select studies including HYRIMOZ.
Sandoz One Source for HYRIMOZ has you covered
Our helpful services provide support around starting, switching to, and staying on HYRIMOZ.
Talk to your doctor to make sure you're enrolled in Sandoz One Source so you can access all the program benefits.
Nurse Ambassadors
- Provide information about financial support options
- Provide injection training support and education about HYRIMOZ
- To request a call from a Nurse Ambassador, fill out the Service Request Form
Co-Pay Card
- For eligible, commercially insured people, the co‑pay offer may be as little as $200. Terms and conditions apply
Other Financial Support Options
- Referral to the Sandoz Patient Assistance Program and independent charitable foundations can provide support for those who are uninsured or underinsured
HYRIMOZ Case Managers
- Help you navigate the insurance process
- Provide reimbursement and authorization support
Sharps Containers
- Free of charge delivery to your home
- Free returns
Welcome Packets
- Everything you need to know when starting HYRIMOZ, delivered directly to your home
Co-Pay Card
- For eligible, commercially insured people, the co‑pay offer may be as little as $0. Terms and conditions applyd
Injection Training
- 1:1 live in-home and virtual options available
QuickStart Program
- Helps you get HYRIMOZ during an insurance authorization delay
Refill Reminders
- Get reminders by phone call or text
Nurse Ambassadors
- Provide information about financial support options
- Provide injection training support and education about HYRIMOZ
Co-Pay Card
- For eligible, commercially insured people, the co‑pay offer may be as little as $0. Terms and conditions applyd
Other Financial Support Options
- Referral to the Sandoz Patient Assistance Program and independent charitable foundations can provide support for those who are uninsured or underinsured
Injection Training
- 1:1 live in-home and virtual options available
HYRIMOZ Case Managers
- Help you navigate the insurance process
- Provide reimbursement and authorization support
QuickStart Program
- Helps you get HYRIMOZ during an insurance authorization delay
Sharps Containers
- Free of charge delivery to your home
- Free returns
Welcome Packets
- Everything you need to know when starting HYRIMOZ, delivered directly to your home
Refill Reminders
- Get reminders by phone call or text
Service Request Form
If you have been prescribed HYRIMOZ, fill out the Service Request Form to access any of the following services:
Request services
Nurse Ambassador, Welcome Packet, Injection Training, or Sharps Container.
Questions?
Call or text SERVICES to 1-833-HYRIMOZ (1-833-497-4669)e
dHYRIMOZ® Co-pay Terms and Conditions: Limitations apply. Valid only for those with private insurance. Prescription must be for an approved indication. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and US Territories (Puerto Rico, Guam, Northern Mariana Islands, and Virgin Islands). This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Sandoz reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.
eMessage and data rates may apply.
Ready to switch from Humira® to HYRIMOZ?
To help patients offset the cost of switching from Humira®, the HYRIMOZ Patient Transition program will provide a one-time reimbursement of $200 to eligible patients in 3 simple stepsf:
Complete the eligibility information at https://portal.trialcard.com/sandoz/hyrimoz.
Upload a copy of a valid HYRIMOZ prescription, filled within the last 90 days, for an approved condition.
Submit the complete eligibility information. Once eligibility has been verified, a $200 healthcare debit card will be sent in the mail.
fThe HYRIMOZ® Patient Transition Program provides a one-time reimbursement of costs to patients who transition from Humira® to HYRIMOZ, in the form of a $200 debit card that the patient must certify will be used for healthcare-related expenses. The following are acceptable merchant codes at which the debit cards can be used: 5912 DRUG STORES, PHARMACIES; 8011 DOCTORS – NOT ELSEWHERE CLASSIFIED; 8050 NURSING AND PERSONAL CARE FACILITIES; 8062 HOSPITALS; 8071 DENTAL AND MEDICAL LABORATORIES; and 8099 HEALTH PRACTITIONERS/MED SVCS UNCLASSIFIED. To qualify, a patient must provide proof of a filled HYRIMOZ prescription for an approved indication dated no more than 90 days prior to applying for the Patient Transition Program. Residents of Illinois, Massachusetts, Michigan, Minnesota, Mississippi, and Rhode Island are not eligible. A patient is not eligible if the patient’s prescription is paid for, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity, or HMO insurance plans that reimburse the patient for the entire cost of the patient’s prescription drugs, or where prohibited by law. Sandoz reserves the right to rescind, revoke, or amend this offer at any time and without further notice.
fThe HYRIMOZ® Patient Transition Program provides a one-time reimbursement of costs to patients who transition from Humira® to HYRIMOZ, in the form of a $200 debit card that the patient must certify will be used for healthcare-related expenses. The following are acceptable merchant codes at which the debit cards can be used: 5912 DRUG STORES, PHARMACIES; 8011 DOCTORS – NOT ELSEWHERE CLASSIFIED; 8050 NURSING AND PERSONAL CARE FACILITIES; 8062 HOSPITALS; 8071 DENTAL AND MEDICAL LABORATORIES; and 8099 HEALTH PRACTITIONERS/MED SVCS UNCLASSIFIED. To qualify, a patient must provide proof of a filled HYRIMOZ prescription for an approved indication dated no more than 90 days prior to applying for the Patient Transition Program. Residents of Illinois, Massachusetts, Michigan, Minnesota, Mississippi, and Rhode Island are not eligible. A patient is not eligible if the patient’s prescription is paid for, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity, or HMO insurance plans that reimburse the patient for the entire cost of the patient’s prescription drugs, or where prohibited by law. Sandoz reserves the right to rescind, revoke, or amend this offer at any time and without further notice.
The HYRIMOZ Sensoready® pen was designed with features you can see, hear, and feel
Sensoready pen features
Using the Sensoready pen
Before your first injection, ask your doctor to show you how to use the Sensoready pen. Additional injection training and support is available through Sandoz One Source for HYRIMOZ.
Using the Sensoready pen
Before your first injection, ask your doctor to show you how to use the Sensoready pen. Additional injection training and support is available through Sandoz One Source for HYRIMOZ.
For complete information on how to inject HYRIMOZ, please see the Instructions for Use section of the Medication Guide.
Frequently Asked Questions (FAQs)
A biosimilar is a biologic medicine that is safe and effective for treating many conditions.
HYRIMOZ is a biosimilar to Humira®. This means HYRIMOZ and Humira® are highly similar and have no clinically meaningful differences when it comes to safety, effectiveness, or quality. While HYRIMOZ is new to the United States, it is not a new medicine. HYRIMOZ has been used in other countries for several years.
- HYRIMOZ offers all you expect from Humira®
- HYRIMOZ delivers results
- Services from Sandoz One Source for HYRIMOZ are available to help ensure a seamless switch
- You can get support right from the start with the HYRIMOZ Patient Transition program
- The Sensoready pen was designed with helpful features to support your injection experience
- HYRIMOZ Patient Transition program: Eligible patients may receive a one-time reimbursement to help offset the cost of switchingg
- Co-pay Card: For eligible, commercially insured people, the co-pay offer may be as little as $0 for HYRIMOZ through this program. Terms and conditions applyd
- Sandoz Patient Assistance (SPA): This program provides HYRIMOZ at no cost to people who qualify. To be considered eligible for SPA, you must:
- Have limited or no insurance coverage for HYRIMOZ
- Meet the program's income requirements
gEligible patients may receive a one-time reimbursement of up to $200 for out-of-pocket costs associated with transitioning to HYRIMOZ to be used for healthcare-related expenses. For patients with commercial insurance only. Must present proof of HYRIMOZ prescription for an approved indication within previous 90 days. Not available in IL, MA, MI, MN, MS, RI, or where prohibited by law. Additional terms and conditions at portal.trialcard.com/sandoz/hyrimoz.
USES
HYRIMOZ® (adalimumab-adaz) is a prescription medicine called a tumor necrosis factor (TNF) blocker used:
- To reduce the signs and symptoms of:
- Moderate to severe rheumatoid arthritis (RA) in adults. HYRIMOZ can be used alone, or with methotrexate, or with certain other medicines. HYRIMOZ may prevent further damage to your bones and joints and may help your ability to perform daily activities
- Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older. HYRIMOZ can be used alone or with methotrexate
- Psoriatic arthritis (PsA) in adults. HYRIMOZ can be used alone or with certain other medicines. HYRIMOZ may prevent further damage to your bones and joints and may help your ability to perform daily activities
- Ankylosing spondylitis (AS) in adults
- Moderate to severe hidradenitis suppurativa (HS) in adults
- To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older
- To treat moderate to severe ulcerative colitis (UC) in adults. It is not known if adalimumab products are effective in people who stopped responding to or could not tolerate TNF-blocker medicines
- To treat moderate to severe chronic (lasting a long time) plaque psoriasis (Ps) in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills)
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about HYRIMOZ?
HYRIMOZ is a TNF-blocker medication that affects your immune system. HYRIMOZ can lower the ability of your immune system to fight infections. You should discuss the potential benefits and risks of HYRIMOZ with your doctor. You should not start taking HYRIMOZ if you have any kind of infection unless your doctor says it is okay.
- Serious infections have happened in people taking adalimumab products. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting HYRIMOZ and check you closely for signs and symptoms of TB during treatment with HYRIMOZ, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB
- Cancer. For children and adults taking TNF blockers, including HYRIMOZ, the chance of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers, including HYRIMOZ, your chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types of cancer are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal
What should I tell my doctor BEFORE starting HYRIMOZ?
Tell your doctor about all of your health conditions, including if you:
- Think you have an infection, are being treated for infection, or have symptoms of an infection, such as:
- Fever, sweats, or chills
- Muscle aches
- Cough
- Shortness of breath
- Blood in phlegm
- Weight loss
- Warm, red, or painful skin or sores on your body
- Diarrhea or stomach pain
- Burning when you urinate or urinating more often than normal
- Feeling very tired
- Get a lot of infections or have infections that keep coming back
- Have diabetes
- Have TB or have been in close contact with someone with TB; or were born in, lived in, or traveled where there is more risk for getting TB
- Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis. These infections may happen or become more severe if you use HYRIMOZ. Ask your doctor if you do not know if you have lived in an area where these infections are common
- Have or have had hepatitis B
- Are scheduled for major surgery
- Have or have had cancer
- Have numbness or tingling or a nervous system disease such as multiple sclerosis or Guillain-Barré syndrome
- Have or had heart failure
- Have recently received or are scheduled to receive a vaccine. You may receive vaccines, except for live vaccines, while using HYRIMOZ. Children should be brought up to date on all vaccines before starting HYRIMOZ
- Are allergic to HYRIMOZ or to any of its ingredients
- Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed
- Have a baby and you were using HYRIMOZ during your pregnancy. Tell your baby's doctor before your baby receives any vaccines
Also tell your doctor about all the medicines you take. You should not take HYRIMOZ with Orencia® (abatacept), Kineret® (anakinra), Remicade® (infliximab), Enbrel® (etanercept), Cimzia® (certolizumab pegol), or Simponi® (golimumab). Tell your doctor if you have ever used Rituxan® (rituximab), Imuran® (azathioprine), or Purinethol® (6-mercaptopurine, 6-MP).
What should I watch for AFTER starting HYRIMOZ?
HYRIMOZ can cause serious side effects, including:
- Serious infections. These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, or loss of body fat and muscle
- Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash
- Allergic reactions. Symptoms of a serious allergic reaction include hives, trouble breathing, and swelling of your face, eyes, lips, or mouth
- Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness
- Blood problems (decreased blood cells that help fight infections or stop bleeding). Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale
- Heart failure (new or worsening). Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain
- Immune reactions including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun
- Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach (abdomen). These problems can lead to liver failure and death
- Psoriasis (new or worsening). Symptoms include red scaly patches or raised bumps filled with pus
Call your doctor or get medical care right away if you develop any of the above symptoms.
What are the most common side effects of HYRIMOZ?
Common side effects of HYRIMOZ include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, and rash.
These are not all the possible side effects with HYRIMOZ. Tell your doctor if you have any side effect that bothers you or that does not go away.
This is the most important information to know about HYRIMOZ. For more information, talk to your doctor or pharmacist.
Please see the full Prescribing Information, including the Medication Guide, for HYRIMOZ.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
HYRIMOZ, the Sandoz One Source logo, and Sensoready are registered trademarks of Novartis AG.
Humira is a registered trademark of AbbVie Biotechnology Ltd.
All other trademarks and trade names are the property of their respective owners.